Guise T A, Yoneda T, Yates A J, Mundy G R
Department of Medicine, University of Texas Health Science Center, San Antonio 78284-7877.
J Clin Endocrinol Metab. 1993 Jul;77(1):40-5. doi: 10.1210/jcem.77.1.8325957.
Humoral hypercalcemia of malignancy is a multifactorial syndrome caused by the action of tumor-produced factors on target organs of bone, kidney, and intestine to disrupt normal calcium homeostasis. Although parathyroid hormone-related protein (PTHrP) plays an integral role in the syndrome, tumors also produce other hypercalcemic factors, such as transforming growth factor-alpha (TGF-alpha), which may modulate the effects of PTHrP. In order to determine if the effects of PTHrP on calcium homeostasis can be modulated by TGF-alpha, we have used a human squamous cell carcinoma cell line (RWGT2) which produces PTHrP alone and Chinese hamster ovarian (CHO) cells expressing only transfected human TGF-alpha complementary DNA (CHO/TGF-alpha). We studied the effects of these tumors on calcium homeostasis in nude mice bearing both tumors or each tumor alone. Whole blood ionized calcium concentrations (mean +/- SEM in mmol/L) were significantly higher in mice bearing both RWGT2 and CHO/TGF-alpha tumors (3.11 +/- 0.06, P < 0.05) when compared with mice bearing either RWGT2 alone (2.02 +/- 0.06), CHO/TGF-alpha alone (1.42 +/- 0.01), or RWGT2 and nontransfected CHO tumors (1.86 +/- 0.01). This enhanced effect was also observed using continuous PTHrP-(1-34) infusion (2 micrograms/day) in mice bearing CHO/TGF-alpha tumors. In addition, tumor cell conditioned media was tested for bone resorbing activity in organ cultures of fetal rat long bones previously incorporated with 45calcium (45Ca++). Conditioned medium at 0.1% (vol/vol) from either RWGT2 or CHO/TGF-alpha had no bone resorbing activity over control (%45Ca++ release, mean +/- SEM; control 23 +/- 1, RWGT2 19 +/- 1, CHO/TGF-alpha 23 +/- 1). However, the combination of 0.1% conditioned medium from RWGT2 and CHO/TGF-alpha significantly increased bone resorption (53 +/- 2, P < 0.05). These data demonstrate that the hypercalcemic effects of tumor-produced PTHrP are enhanced by TGF-alpha and that this effect may be due to increased bone resorption.
恶性肿瘤体液性高钙血症是一种多因素综合征,由肿瘤产生的因子作用于骨骼、肾脏和肠道等靶器官,破坏正常的钙稳态所致。虽然甲状旁腺激素相关蛋白(PTHrP)在该综合征中起重要作用,但肿瘤也会产生其他导致高钙血症的因子,如转化生长因子-α(TGF-α),它可能会调节PTHrP的作用。为了确定TGF-α是否能调节PTHrP对钙稳态的影响,我们使用了一种仅产生PTHrP的人鳞状细胞癌细胞系(RWGT2)和只表达转染的人TGF-α互补DNA的中国仓鼠卵巢(CHO)细胞(CHO/TGF-α)。我们研究了这些肿瘤对单独携带这两种肿瘤或每种肿瘤的裸鼠钙稳态的影响。与单独携带RWGT2(2.02±0.06)、单独携带CHO/TGF-α(1.42±0.01)或携带RWGT2和未转染的CHO肿瘤(1.86±0.01)的小鼠相比,同时携带RWGT2和CHO/TGF-α肿瘤的小鼠全血离子钙浓度(以mmol/L为单位的平均值±标准误)显著更高(3.11±0.06,P<0.05)。在携带CHO/TGF-α肿瘤的小鼠中,使用连续输注PTHrP-(1 - 34)(2微克/天)也观察到了这种增强效应。此外,在预先掺入45钙(45Ca++)的胎鼠长骨器官培养物中,检测了肿瘤细胞条件培养基的骨吸收活性。来自RWGT2或CHO/TGF-α的0.1%(体积/体积)条件培养基与对照相比没有骨吸收活性(45Ca++释放百分比,平均值±标准误;对照23±1,RWGT2 19±1,CHO/TGF-α 23±1)。然而,来自RWGT2和CHO/TGF-α的0.1%条件培养基的组合显著增加了骨吸收(53±2,P<0.05)。这些数据表明,肿瘤产生的PTHrP的高钙血症效应会被TGF-α增强,并且这种效应可能是由于骨吸收增加所致。